- Investor's Business Daily•41 minutes ago
Biotech stocks have nearly "round-tripped" their Donald Trump-inspired rally.
- Reuters•46 minutes ago
Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to cause less risk of brain swelling than higher fixed doses, according to interim 12-month results from a small study released on Thursday. The closely watched drug, aducanumab, led to significant reductions in amyloid plaques in the brain compared with a placebo among the 31 patients who received titrated, or gradually increased dosing, data from the Phase I study showed. "Incidence of the most common adverse event appeared to be lower with titrated dosing compared with higher fixed dosing of aducanumab," researchers, in a brief summary of the results, said of the brain swelling known as ARIA.
- American City Business Journals•56 minutes ago
Shares of Cambridge-based Biogen rose slightly on Thursday after positive data from an upcoming presentation on its experimental Alzheimer’s drug was leaked online. Biogen (BIIB) is scheduled to present early-stage data on aducanumab at a medical industry conference in San Diego on Friday, but an embargoed abstract of the presentation was apparently leaked Thursday afternoon. Shares of Biogen were up about 1.5 percent at the close of trading.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||281.09 x 100|
|Ask||289.50 x 100|
|Day's Range||278.58 - 292.97|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.37|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|